New hope for kids with brain cancer? LAM561 trial launches

NCT ID NCT04299191

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an oral drug called LAM561 in children under 18 with advanced brain tumors (like high-grade glioma) or other solid tumors that have not responded to standard treatments. The trial has two phases: first, finding a safe dose in up to 18 children, then testing that dose in another 10 children to confirm safety. The goal is to see if LAM561 can control the disease and to determine the best dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
LAM561 (an oral drug)
What this could lead to
If it works, this could point toward a new treatment option for children with hard-to-treat brain tumors.
What could go wrong
This is an early-phase trial with only 28 participants, so the drug may not prove effective or may have side effects. It is not a cure and long-term benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Arkansas Children's Research Institute

    RECRUITING

    Little Rock, Arkansas, 72202, United States

  • Hackensack Meridian Health, Inc

    RECRUITING

    Edison, New Jersey, 08837, United States

  • University of Miami Hospital

    RECRUITING

    Miami, Florida, 33146, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.